LOS ANGELES, CA - When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls gene expression, influenced by factors such as diet, stress, exercise, and exposure to toxins. This means that even without a family history of heart disease, an individual’s epigenetic profile can reveal elevated risk due to their unique experiences and choices.
For readers, this has significant implications. Traditional risk assessments often rely on static genetic markers, but epigenetics offers a dynamic view of current health status. Cardio Diagnostics’ tests could help identify hidden risks that standard screenings might miss, allowing for earlier intervention and personalized prevention strategies. The company’s platform thus represents a shift toward more proactive and precise cardiovascular care.
The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. For more information on terms of use and disclaimers, see http://IBN.fm/Disclaimer.
